Scarica l'app Stockscreener
0.241
0.00%
0.00
Dopo l'orario di chiusura:
.25
0.009
+3.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.241
Aprire:
$0.2438
Volume 24 ore:
792.61K
Relative Volume:
0.42
Capitalizzazione di mercato:
$9.89M
Reddito:
$1.04M
Utile/perdita netta:
$-67.50M
Rapporto P/E:
-0.1254
EPS:
-1.9222
Flusso di cassa netto:
$-60.67M
1 W Prestazione:
+6.45%
1M Prestazione:
+6.64%
6M Prestazione:
-56.83%
1 anno Prestazione:
-91.60%
Intervallo 1D:
$0.236
$0.251
Intervallo di 1 settimana:
$0.217
$0.252
Portata 52W:
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.241 | 9.45M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics, Inc. Revenue Breakdown – BMV:VTGN - TradingView
TradingKey - TradingKey
VTGN|Vistagen Therapeutics Inc|Price:0.226|Chg%:+0.000 - TradingKey
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Yahoo Finance
VTGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTGN Stockholders Have Opportunity to Lead Vistagen Therapeutics - The National Law Review
VistaGen Therapeutics (VTGN) TD Cowen 45th Annual Health Care Conference Summary - Quartr
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Penny stock Vistagen keeps regulatory plans alive despite anxiety study miss - MSN
Enterprise value to revenue forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Price to sales forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing - Stock Titan
Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly - Stock Titan
ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares - Stock Titan
$VistaGen Therapeutics (VTGN.US)$ - Moomoo
VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
VistaGen pivots fasedienol toward long-term anxiety treatment - The Globe and Mail
Vistagen Therapeutics (VTGN) Q2 2026 Earnings: EPS Miss and Stock Plunge as Pre-Revenue Biotech Faces R&D HeadwindsMargin Compression Risk - DonanımHaber
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, In - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review
Vistagen’s anxiety disorder drug misses main goal in late-stage trial, shares plummet - Classic Rock 103.5 WIMZ
symbol__ Stock Quote Price and Forecast - CNN
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder. - Bitget
Vistagen fails another phase 3 anxiety trial, spies path forward - Fierce Biotech
Vistagen (VTGN) Reports Phase 3 Trial Results for Fasedienol - GuruFocus
VTGN: Post-hoc analyses show fasedienol benefits very severe social anxiety, guiding a new LSAS-based trial - TradingView
Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup - TradingView
Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal - Stock Titan
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BMV:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN) - TradingView
VTGN Forecast — Price Target — Prediction for 2027 - TradingView
Vistagen Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesEarnings Sentiment Score - dars.gov.et
Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth - The Globe and Mail
Vistagen Therapeutics directors to step down after 2026 annual meeting - Investing.com UK
Vistagen Therapeutics directors to step down after 2026 annual meeting By Investing.com - Investing.com India
Vistagen Therapeutics Inc (VTGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting - Stock Titan
Vistagen Therapeutics Inc (VTGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vistagen Therapeutics Inc (VTGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vistagen Therapeutics Inc (VTGN) Institutional Confidence - TradingKey
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - BioSpace
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):